Citations

Clear

6 citation(s) found for "Chen, Lee-may".

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Slomovitz, Brian M. , Weroha, S. John , Chon, Hye Sook, Podder, Vivek , Markham, Merry Jennifer , Backes, Floor , Thomas, Eric D. , Tenney, Meaghan , Miller, David S. , Muller, Carolyn Y., Callahan, Michael J. , Liu, J. Rebecca, Teplinsky, Eleonora , Kamat, Aparna A., Chern, Jing‐Yi , Murphy, Martina, Choong, Grace M. , Moore, Elena Diaz, Alvarez, Edwin , Rodgers, William H. , Copeland, Larry J. , Herzog, Thomas J. , Podder, Vivek , Markham, Merry J , Backes, Floor , Tenney, Meaghan Elizabeth , Westin, Shannon N , Miller, David S , Edelson, Mitchell I , Teplinsky, Eleonora , Guy, Michael , Choong, Grace M , O'Malley, David M , Copeland, Larry J , Herzog, Thomas J , Coleman, Robert , Gershenson, David M , Deng, Wei, Chen, Lee-may , Edelson, Mitchell I. , Holman, Laura L. , Lea, Jayanthi Sivasothy , O’Malley, David M. , Coleman, Robert L. , Gershenson, David M.

Mayo Clinic

Journal of Clinical Oncology | December 12, 2025 | Volume: 44 | Issue: 3 | Pages: 153-163

10.1200/jco-25-01348 | PMID 41385758 Get It

PURPOSE Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519

10.6004/jnccn.2024.0052 | PMID 39413835 Get It

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Armstrong, Deborah K. , Barroilhet, Lisa , Chitiyo, Viola C., Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , McHale, Michael , Miller, David S. , Percac‐Lima, Sanja , Remmenga, Steven W., Schorge, John O., Vargas, Roberto , Hendrickson, Andrea Wahner, Werner, Theresa L. , Dwyer, Mary A., Hang, Lisa E., Miller, David S , Alvarez, Ronald D. , Backes, Floor , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Chitiyo, Viola, DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Leiserowitz, Gary S. , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen , Stewart, Daphne B. , Thaker, Premal H. , Zsíros, Emese

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 8, 2022 | Volume: 20 | Issue: 9 | Pages: 972-980

10.6004/jnccn.2022.0047 | PMID 36075393 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Chen, Lee-may, Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , Mahdi, Haider , McHale, Michael , Miller, David S. , O’Malley, David M. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Vargas, Roberto , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Miller, David S , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 8, 2021 | Volume: 19 | Issue: 2 | Pages: 191-226

10.6004/jnccn.2021.0007 | PMID 33545690 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.